Introduction

Alzheimer’s disease, a progressive neurodegenerative disorder, is one of the most common causes of dementia worldwide. It profoundly affects the lives of those diagnosed, causing memory loss, cognitive impairment, and behavioural changes that worsen over time. While much focus is placed on the cognitive symptoms of Alzheimer’s, the emotional and psychological impacts are equally significant. Anxiety is a particularly distressing symptom in patients with Alzheimer’s, as it not only causes personal suffering but also complicates caregiving and overall disease management. Finding safe and effective treatments for anxiety in Alzheimer’s patients remains a pressing challenge.

The role of CBD

Cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant, has gained attention for its potential therapeutic effects, including its ability to alleviate anxiety. Unlike tetrahydrocannabinol (THC), another prominent compound in cannabis, CBD does not produce the “high” associated with marijuana use. Instead, CBD interacts with various biological systems in the body to promote relaxation and reduce stress. Its growing popularity stems from its perceived safety profile and potential to serve as an alternative to traditional anxiety medications. For Alzheimer’s patients, whose advanced age and medical fragility make them particularly vulnerable to side effects, CBD could represent a promising treatment option.

Anxiety in Alzheimer’s disease manifests in various ways and is influenced by multiple factors. Patients may experience fear and restlessness as they lose their ability to remember events, recognise familiar people, or understand their surroundings. This cognitive decline is often accompanied by changes in brain structure and function, particularly in regions responsible for processing emotions, such as the hippocampus and amygdala. External stressors, such as changes in the environment or routine, can further exacerbate anxiety. The combination of internal neurobiological changes and external triggers creates a complex challenge for caregivers and medical professionals.

Traditionally, anxiety in Alzheimer’s patients is treated with medications such as benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), or antipsychotics. While these drugs can provide relief, they often come with significant drawbacks. Sedation, dizziness, increased fall risk, and negative interactions with other medications are common concerns, especially for elderly patients. Moreover, the overuse of such medications can lead to dependency and other long-term complications. This has led researchers and clinicians to explore alternative therapies, including CBD, which may offer a more balanced approach to managing anxiety in this vulnerable population.

CBD’s effects on anxiety are thought to be mediated through its interaction with several key biological systems. One of the primary pathways is the endocannabinoid system (ECS), a regulatory system in the body that plays a crucial role in maintaining balance across various physiological processes. The ECS consists of cannabinoid receptors (CB1 and CB2), endocannabinoids produced by the body, and enzymes that break them down. By interacting with these receptors, CBD can help regulate mood, reduce stress responses, and promote a sense of calm. Specifically, CBD is believed to increase levels of anandamide, a naturally occurring endocannabinoid often referred to as the “bliss molecule,” by inhibiting its breakdown.

In addition to its effects on the ECS, CBD influences serotonin receptors in the brain. Serotonin is a neurotransmitter that regulates mood, anxiety, and overall emotional well-being. CBD’s ability to enhance serotonin receptor activity mimics the mechanism of SSRIs, which are commonly prescribed for anxiety and depression. However, CBD may achieve similar benefits without the side effects frequently associated with these medications, such as gastrointestinal issues, weight gain, or sexual dysfunction.

Another important aspect of CBD’s action is its potential to reduce overactivity in the amygdala, the part of the brain responsible for processing fear and threat-related stimuli. Hyperactivity in this region is a hallmark of anxiety disorders, and calming the amygdala may help Alzheimer’s patients feel less overwhelmed by their environment. Additionally, Alzheimer’s disease is often accompanied by chronic inflammation in the brain, which can worsen anxiety and other behavioural symptoms. CBD’s anti-inflammatory properties may indirectly alleviate anxiety by addressing the underlying neuroinflammation that contributes to emotional distress.

Scientific research on CBD’s effects on anxiety has produced promising results, although specific studies on Alzheimer’s patients remain limited. Preclinical studies using animal models have demonstrated that CBD reduces anxiety-related behaviours and improves social interactions. These effects have been attributed to its impact on both serotonin signalling and the ECS. In rodent models of Alzheimer’s disease, CBD has also shown neuroprotective properties, potentially slowing the progression of neurodegeneration while simultaneously reducing anxiety symptoms.

Human studies, while fewer in number, have also supported the anxiolytic effects of CBD. Clinical trials involving individuals with generalised anxiety disorder, social anxiety, and post-traumatic stress disorder have consistently reported reductions in anxiety levels following CBD administration. In one notable study, participants who took a single dose of CBD before a public speaking task experienced significantly reduced anxiety compared to those given a placebo. These findings are encouraging for Alzheimer’s patients, as the physiological mechanisms underlying anxiety in different conditions often overlap.

There is also emerging evidence that CBD may improve behavioural symptoms associated with dementia, including agitation and restlessness. These symptoms often overlap with anxiety and can be particularly challenging to manage in Alzheimer’s patients. Small-scale studies and anecdotal reports suggest that CBD can promote relaxation and improve sleep in dementia patients, providing indirect benefits for anxiety management. For example, a case series involving elderly patients with dementia found that daily use of CBD reduced anxiety and restlessness by approximately 40% over a four-week period, with no serious side effects reported.

Despite these promising findings, there are challenges and limitations associated with the use of CBD in Alzheimer’s care. One of the primary concerns is the lack of standardised dosing guidelines. The appropriate dose of CBD for anxiety relief in Alzheimer’s patients is not yet well-defined, and individual responses can vary based on factors such as age, weight, disease 

severity, and concurrent medications. Starting with a low dose and gradually increasing under medical supervision is generally recommended.

Another significant issue is the variability in product quality within the CBD market. Due to inconsistent regulations, many CBD products lack third-party testing or contain inaccurate labelling, leading to concerns about purity and potency. Caregivers and healthcare providers must ensure that any CBD product used is sourced from a reputable manufacturer that provides transparent lab testing results. Additionally, CBD can interact with other medications commonly prescribed for Alzheimer’s patients, such as anticoagulants or antiepileptic drugs. Monitoring for potential drug interactions is essential to ensure patient safety.

Future recommendations

Future research is needed to better understand CBD’s role in managing anxiety in Alzheimer’s patients. Large-scale clinical trials should be conducted to confirm its efficacy and safety, establish optimal dosing protocols, and evaluate long-term effects. Researchers should also explore the potential of combining CBD with other therapeutic approaches, such as cognitive behavioural therapy or mindfulness practices, to enhance outcomes. Additionally, the development of formulations specifically tailored for elderly patients, such as easy-to-administer tinctures or capsules, could improve accessibility and adherence.

While there is still much to learn, CBD offers a promising alternative for managing anxiety in Alzheimer’s patients. Its ability to interact with key biological systems, coupled with its favourable safety profile, positions it as an attractive option for those seeking relief from anxiety without the drawbacks of traditional medications. However, its use should be approached cautiously and always under medical supervision, particularly given the current lack of regulatory oversight and standardised guidelines. For Alzheimer’s patients and their caregivers, CBD represents a hopeful avenue in the quest for better emotional and psychological support. With further research and careful implementation, it could become an integral part of comprehensive Alzheimer’s care, improving quality of life for both patients and their families.

Conclusion

Anxiety is a common and challenging symptom in Alzheimer’s patients, significantly affecting their quality of life and complicating caregiving. Traditional anxiety treatments, like benzodiazepines and SSRIs, often have severe side effects, particularly in elderly populations. Cannabidiol (CBD), a non-psychoactive compound derived from cannabis, has shown potential as a safer alternative due to its anxiolytic and anti-inflammatory properties.

CBD works by interacting with the endocannabinoid system (ECS) and serotonin receptors, helping to regulate mood and reduce stress responses. It also addresses inflammation and amygdala overactivity, which are linked to anxiety in Alzheimer’s patients. Although preclinical studies and limited human research suggest CBD’s effectiveness in reducing anxiety, specific studies on Alzheimer’s patients remain scarce. Nonetheless, anecdotal evidence and small-scale studies highlight its potential to improve behavioural symptoms like restlessness and agitation in dementia patients.